New drug safety with radiation and chemo for newly diagnosed glioblastoma
Part of Cancer clinical trials.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a new brain cancer called glioblastoma that has not been treated yet, and your tumor must have the MGMT methylated feature.
- You should be able to take care of yourself (fully active or able to do light activities) — your doctor will check this.
- Your heart, liver, and kidney function must be within acceptable limits — your doctor will test this.
- If you are taking steroids for brain swelling, the dose must have been stable for at least 2 weeks before starting the study.
- You must agree to use effective birth control if you or your partner could become pregnant, and you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the drug ruxolitinib to standard radiation and chemotherapy (temozolomide) helps people with a newly diagnosed brain tumor called glioblastoma. It aims to see if the combination keeps the tumor from growing longer than the standard treatment alone.
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.